15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The role of the tumour microenvironment in the angiogenesis of pituitary tumours

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Angiogenesis has been studied in pituitary neuroendocrine tumours (PitNETs), but the role of the tumour microenvironment (TME) in regulating PitNET angiogenesis remains unknown. We aimed to characterise the role of TME components in determining the angiogenetic PitNET profile, focusing on immune cells and tumour-derived cytokines.

          Methods

          Immune cells were studied by immunohistochemistry in 24 human PitNETs (16 non-functioning-PitNETs (NF-PitNETs) and 8 somatotrophinomas): macrophages (CD68, CD163, HLA-DR), cytotoxic (CD8) and T helper (CD4) lymphocytes, regulatory T cells (FOXP3), B cells (CD20) and neutrophils (neutrophil elastase); endothelial cells were assessed with CD31. Five normal pituitaries (NP) were included for comparison. Microvessel density and vascular morphology were estimated with ImageJ. The cytokine secretome from these PitNETs were assessed on culture supernatants using a multiplex immunoassay panel.

          Results

          Microvessel density/area was higher in NP than PitNETs, which also had rounder and more regular vessels. NF-PitNETs had vessels of increased calibre compared to somatotrophinomas. The M2:M1 macrophage ratio correlated with microvessel area. PitNETs with more CD4+ T cells had higher microvessel area, while tumours with more FOXP3+ cells were associated with lower microvessel density. PitNETs with more B cells had rounder vessels. Of the 42 PitNET-derived cytokines studied, CCL2, CXCL10 and CX3CL1 correlated with microvessel density and vessel architecture parameters.

          Conclusions

          M2 macrophages appear to play a role in PitNET neovascularisation, while B, CD4+ and FOXP3+ lymphocytes, as well as non-cellular TME elements such as CCL2, CXCL10 and CX3CL1, may also modulate the angiogenesis of PitNETs.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

          Mononuclear phagocytes are versatile cells that can express different functional programs in response to microenvironmental signals. Fully polarized M1 and M2 (or alternatively activated) macrophages are the extremes of a continuum of functional states. Macrophages that infiltrate tumor tissues are driven by tumor-derived and T cell-derived cytokines to acquire a polarized M2 phenotype. These functionally polarized cells, and similarly oriented or immature dendritic cells present in tumors, have a key role in subversion of adaptive immunity and in inflammatory circuits that promote tumor growth and progression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Molecular mechanisms and clinical applications of angiogenesis.

            Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Fibroblasts in cancer.

              Tumours are known as wounds that do not heal - this implies that cells that are involved in angiogenesis and the response to injury, such as endothelial cells and fibroblasts, have a prominent role in the progression, growth and spread of cancers. Fibroblasts are associated with cancer cells at all stages of cancer progression, and their structural and functional contributions to this process are beginning to emerge. Their production of growth factors, chemokines and extracellular matrix facilitates the angiogenic recruitment of endothelial cells and pericytes. Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies.
                Bookmark

                Author and article information

                Contributors
                m.korbonits@qmul.ac.uk
                Journal
                Endocrine
                Endocrine
                Endocrine
                Springer US (New York )
                1355-008X
                1559-0100
                18 September 2020
                18 September 2020
                2020
                : 70
                : 3
                : 593-606
                Affiliations
                [1 ]GRID grid.4868.2, ISNI 0000 0001 2171 1133, Centre for Endocrinology, William Harvey Research Institute, , Barts and the London School of Medicine and Dentistry, Queen Mary University of London, ; London, UK
                [2 ]Department of Pathology, STHF, Skien, Norway
                [3 ]GRID grid.436283.8, ISNI 0000 0004 0612 2631, The National Hospital for Neurology and Neurosurgery, UCLH, NHS Trust, ; London, UK
                [4 ]GRID grid.7445.2, ISNI 0000 0001 2113 8111, Department of Neurosurgery, , Charing Cross Hospital, Imperial College, ; London, UK
                [5 ]GRID grid.413628.a, ISNI 0000 0004 0400 0454, Department of Neurosurgery, , Derriford Hospital, ; Plymouth, UK
                Author information
                http://orcid.org/0000-0002-4101-9432
                Article
                2478
                10.1007/s12020-020-02478-z
                7674353
                32946040
                c9fa4752-d2ce-4490-b05a-6ef880649227
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 25 June 2020
                : 23 August 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/, Barts and The London Charity (BTLC);
                Categories
                Original Article
                Custom metadata
                © Springer Science+Business Media, LLC, part of Springer Nature 2020

                Endocrinology & Diabetes
                pituitary neuroendocrine tumour,pituitary adenoma,tumour microenvironment,cytokine,immune cell,angiogenesis

                Comments

                Comment on this article